{"id":"W3211527733","doi":"10.1182/blood-2021-154279","title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Venetoclax; Obinutuzumab; Medicine; Internal medicine; Oncology; Pembrolizumab; Rituximab; Cancer; Immunotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002443903,0.0001526075,0.0004333957,0.0001476452,0.00023929,0.0003785744,0.0001931866,0.0002613388,0.003497388],"category_scores_gemma":[0.0003857207,0.0000732401,0.0004221729,0.0001946495,0.000128675,0.0002339223,0.0001931271,0.0007615007,0.0004129156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004541003,"about_ca_system_score_gemma":0.0005849533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006318523,"about_ca_topic_score_gemma":0.002748292,"domain_scores_codex":[0.9999177,0.00002298484,0.000008996271,0.00001601103,0.00001177914,0.00002253859],"domain_scores_gemma":[0.9998345,0.00003562585,0.00003994247,0.000006862569,0.00001271179,0.00007024402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09691212,0.00354542,0.09108079,0.002299678,0.0006796935,0.003470212,0.0003783418,0.001238535,0.0316522,0.0009447262,0.04489075,0.7229076],"study_design_scores_gemma":[0.1346482,0.1626812,0.4006138,0.002382435,0.003092909,0.03477111,0.0008008588,0.006838882,0.02966283,0.003436429,0.220942,0.0001294767],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9429492,0.03429376,0.0006866786,0.00341725,0.0002320224,0.0006071985,0.001325112,0.0001918144,0.016297],"genre_scores_gemma":[0.9895976,0.004051945,0.0008984847,0.001594947,0.0001058044,0.000169717,0.001007245,0.000009681629,0.00256471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003497388,"threshold_uncertainty_score":0.01169991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01555827402009516,"score_gpt":0.2694863837476252,"score_spread":0.25392810972753,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}